More importantly, a 30 or 10 mg/kg BID dose of SY-1530 displayed a better effect on blocking BCR signaling pathway than a 100 or 30 mg/kg QD dose, in agreement with the in vivo anti-tumor activities. The gene discussed is BCR; the disease is neoplasm.